 | Up a level |
Lazarus, Jeffrey V; Mark, Henry E; Allen, Alina M; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N; Burra, Patrizia; Castro-Narro, Graciela E; Cortez-Pinto, Helena; Cusi, Kenneth; Dedes, Nikos; Duseja, Ajay; Francque, Sven M; ... (2023). A global research priority agenda to advance public health responses to fatty liver disease. Journal of hepatology, 79(3), pp. 618-634. Elsevier 10.1016/j.jhep.2023.04.035
Sanyal, Arun J; Anstee, Quentin M; Trauner, Michael; Lawitz, Eric J; Abdelmalek, Manal F; Ding, Dora; Han, Ling; Jia, Catherine; Huss, Ryan S; Chung, Chuhan; Wong, Vincent Wai-Sun; Okanoue, Takeshi; Romero-Gomez, Manuel; Muir, Andrew J; Afdhal, Nezam H; Bosch, Jaime; Goodman, Zachary; Harrison, Stephen A; Younossi, Zobair M and Myers, Robert P (2022). Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. Hepatology, 75(5), pp. 1235-1246. Wiley 10.1002/hep.32204
Loomba, Rohit; Huang, Daniel Q.; Sanyal, Arun J; Anstee, Quentin Mark; Trauner, Michael; Lawitz, Eric J; Ding, Dora; Ma, Lily; Jia, Catherine; Billin, Andrew; Huss, Ryan S; Chung, Chuhan; Goodman, Zachary; Wong, Vincent Wai-Sun; Okanoue, Takeshi; Romero-Gómez, Manuel; Abdelmalek, Manal F; Muir, Andrew; Afdhal, Nezam; Bosch, Jaime; ... (2022). Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut, 72(3), pp. 581-589. BMJ Publishing Group 10.1136/gutjnl-2022-327777
Younossi, Zobair M; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M; Goodman, Zachary; Bedossa, Pierre; Geier, Andreas; Beckebaum, Susanne; Newsome, Philip N; Sheridan, David; Sheikh, Muhammad Y; Trotter, James; Knapple, Whitfield; Lawitz, Eric; Abdelmalek, Manal F; Kowdley, Kris V; Montano-Loza, Aldo J; Boursier, Jerome; Mathurin, Philippe; ... (2019). Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 394(10215), pp. 2184-2196. Elsevier 10.1016/S0140-6736(19)33041-7
